Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with companies executive. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Recently Added News
J&J Vision Gains US Approval of TECNIS Synergy and Synergy Toric II, Canadian Approval of Toric II
Johnson & Johnson Vision announced May 6 that it had gained US FDA approval for its TECNIS Synergy and Synergy Toric II IOLs, plus Health Canada approval for the Synergy Toric II IOLs. The Synergy ...
Ziemer Introduces Femto Z8 Neo Multipurpose Cataract-Refractive Laser
Swiss company Ziemer has introduced a new femtosecond laser, the Femto Z8 Neo—the successor to its LDV Z8. The multipurpose cataract, refractive, and therapeutic laser system has a small, wheeled p...
Ophtec Introduces PC-Toric Version of its Precizon IOL
Dutch company Ophtec announced May 1 that it had introduced the Precizon Presbyopic Toric IOL, which combines the features of the company’s Precizon Toric and Precizon Presbyopic lenses. Ophtec tou...
Q1-2021 Revenue Roundup: Alcon, Bausch + Lomb, Regeneron, Eight More
Alcon reported May 4 that its Q1-2021 net sales totaled $1.9 billion, a 5 percent increase over $1.8 billion in Q1-2020. David Endicott, chief executive officer, called the first quarter a solid st...
Lumenis Receives US FDA Approval for OptiLight IPL Device to Manage Dry Eye
Israel’s Lumenis announced April 29 that the US FDA had granted de novo authorization for OptiLight, the company’s newest intense pulsed light (IPL) device for improving signs of dry eye disease du...
Sandoz Readies for Phase III Trial of Proposed Aflibercept Biosimilar
Novartis’ Sandoz division said May 3 that it was in late-stage development of a proposed biosimilar of retinal drug aflibercept (Eylea). Sandoz said it would begin enrolling the first patient in a ...
US Appeals Court Ruling Prevents FDA from Regulating Devices as Drugs
A US appeals court ruling April 16 will make it harder for the FDA to regulate medical technology as a drug when it meets the definition of a device. The decision by the DC Circuit Court of Appeals...
FDA to Create New Method for Approving Old Drugs
The US FDA is reviewing how to replace the Unapproved Drugs Initiative, a program launched in 2006 to encourage manufacturers to seek approval for drugs that were in use before 1938, when the FDA b...
Aldeyra Raises $125 Million in Public Offering of Common Stock
Aldeyra Therapeutics announced April 27 the pricing of a public offering of 10 million shares of its common stock at $12.50 per share, for gross proceeds of $125 million. The Lexington, Massachuset...
Biophytis Receives $1.2 Million DeepTech Funding from BPI France for Dry AMD Candidate
Biophytis announced April 29 that it was granted a non-dilutive funding of €980 thousand ($1.2 million) from the public investment bank BPI France’s DeepTech program to advance Macuneos (BIO201) in...
Oculis Raises $57 Million in Oversubscribed Series C Financing
Swiss company Oculis announced May 4 that it had closed an oversubscribed $57 million Series C financing. The round was co-led by new investors BVCF Management and Hyfinity Investments, with VI Par...
twoXAR Rebrands as Aria; Pipeline Includes Glaucoma Candidate
Palo Alto, California, company twoXAR announced May 4 that the company has rebranded as Aria Pharmaceuticals. The company said it would transition from drug discovery partnerships to advancing its ...
Past News Stories
Ceyeber, Founded by Robert Grant, Secures US Patent Protecting Interactive IOL
Ceyeber, an IOL developer founded in 2020 by ophthalmic industry veteran Robert Grant, announced in late April and early May that it had secured a US patent for its interactive IOL technology and a...
Mogrify Completes Series A Financing Totaling $33 Million
British biopharmaceutical company Mogrify announced May 4 that it had closed a second Series A financing of $17 million, bringing the total raised in the round to $33 million. Investors included Pa...
OcuTerra Names Brent Saunders as Chairman
Boston-based OcuTerraTherapeutics, formerly SciFluor Life Sciences, has named ophthalmic industry veteran Brent Saunders as chairman of its board. The company is advancing OTT166, a small molecule ...
Backlog of 6 Million Cataract Surgeries Will Help Drive IOL Market through 2026
Pandemic-impacted 2020 led to a backlog of more than 6 million cataract surgeries globally, as procedures declined 25 percent to 22 million, the lowest number since 2010, mainly due to COVID-relate...
Adverum Reports Vision Loss in Patient Treated in Phase II DME Trial
Adverum Biotechnologies reported April 28 that a patient in its Phase II INFINITI study developed hypotony, with panuveitis and loss of vision, in one eye 30 weeks after the eye received a high dos...
Alcon Returns to Glaucoma Pharma Segment with Purchase of Simbrinza
Alcon announced April 28 that it had agreed to acquire US commercialization rights to glaucoma drug Simbrinza from former parent Novartis in a move to return to the glaucoma pharmaceuticals segment...
Q1-2021 Revenue Roundup for J&J Vision, Lumibird, Novartis, and Three Others
J&J Vision’s surgical unit posted Q1-2021 revenue of $288 million, a 13.7 percent increase over $253 million in Q1-2020, parent Johnson & Johnson, of New Brunswick, New Jersey, announced April 20. ...
All India Ophthalmological Society Reconsiders Annual Meeting
The All India Ophthalmological Society (AIOS) no longer plans to hold an in-person annual meeting in June, but now the society appears to be considering whether to hold a meeting at all. The AIOS i...
Surgical Specialties is Now Corza Medical, Following Sale and Merger
Surgical Specialties has become Corza Medical after its sale and merger with TachoSil Fibrin Sealant Patch in February. The news was announced Feb. 1 by private equity firm GTCR, of Chicago. Surgic...
Glaukos Adds Presbyopia as Potential Indication for Licensed Eyelid Cream
Glaukos, of San Clemente, California, reported April 22 that it had amended its licensing agreement with Intratus to add presbyopia as a targeted treatment. Glaukos secured a global exclusive licen...
Oertli Introduces Updated OS 4 Console for Retina, Glaucoma, and Cataract Surgery
Oertli introduced on April 22 the next generation of its OS 4 surgical platform for retinal, glaucoma, and cataract surgery. New features include: —A fully automated laser user protection filter th...
SIFI Initiates Phase II Trial of Progesterone Topical Gel in Dry Eye
Italian company SIFI announced April 27 that the first patients had been enrolled in its Phase II trial evaluating Pro-ocular, a progesterone based topical gel, in patients with dry eye disease (DE...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.